



Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Edwards

Phone: 650-351-4730

E-mail:

investor@globalbloodtx.com

Stock Performance

GBT (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$44.00
Change (%)	▼ 1.7 (3.72%)
Volume	3,059,085
52 Week Low	\$13.35
Market Cap	\$1,997,059,792
Rolling EPS	-2.55
PE Ratio	0
Shares Outstanding	43,699,339

Data as of 12/11/17 1:30 p.m. ET



Recent Headlines & Events

12/11/17

[GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease \(SCD\) Program](#)

12/09/17

[GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease \(SCD\)](#)

11/30/17

[Global Blood Therapeutics Announces New Employment Inducement Grants](#)

Date Title

12/11/17 8:15 p.m. ET **[GBT Investor Webcast from the American Society of Hematology \(ASH\) 2017 Annual Meeting](#)**

SEC Filings

Filing Date	Form
11/21/17	<u>4</u>
11/13/17	<u>8-K</u>
11/02/17	<u>10-Q</u>
11/02/17	<u>8-K</u>

Corporate Governance

<u>Ted W. Love, M.D.</u>	Chief Executive Officer
<u>Jeffrey Farrow</u>	Chief Financial Officer
<u>Jung E. Choi</u>	Chief Business and Strategy Officer
<u>Tricia Suvari</u>	Chief Legal Officer
<u>Hing Sham, Ph.D.</u>	Senior Vice President, Research
<u>Peter Radovich</u>	Vice President, Program Leadership and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.